Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes

Atopic dermatitis (AD) significantly impacts physical, social, and psychological well-being. Recently, novel, more effective treatment options have been approved, including those targeting interleukin-13. Watch this webcast for expert insights on incorporating these agents to optimize care for patients with moderate to severe AD.

Share

Program Content

Activities

Targeting IL-13 for AD Care
Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes
Video
Congratulations: You achieved a completion on 04/09/2022

Released: May 15, 2023

Expires: May 14, 2024

Activities

Targeting IL-13 for AD Slides
Slides on Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 10, 2023

Activities

IL-13 Inhibitors for AD CT
Expert Commentary on the Use of IL-13 Inhibition in Treating Moderate to Severe Atopic Dermatitis
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 19, 2023

Faculty

cover img faculity

Terry Faleye, MPAS, PA-C

Dermsurgery Associates – Kingwood
Houston, Texas

cover img faculity

Jonathan Silverberg, MD, PhD, MPH

Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Provided by

ProCE Banner

Provided by Partners for Advancing Clinical Education (PACE)

Supporters

This activity is supported by an educational grant from Lilly.

Lilly